Understand the source comparison
NAD+ Epithalon Stack Protocol: Comparison Table
Researchers often ask whether to dose NAD+ and Epithalon together or separately, and whether to follow continuous or pulsed administration schedules. The table below compares three common protocol structures based on published research models and investigator-
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Researchers often ask whether to dose NAD+ and Epithalon together or separately, and whether to follow continuous or pulsed administration schedules. The table below compares three common protocol structures based on published research models and investigator-reported outcomes.
- Pulsed Dual Stack
- 50–100 mg daily or every other day
- 5–10 mg daily for 10–20 days
- NAD+ morning, Epithalon evening, during overlapping 10–20 day window
- 10–20 days active, 4–6 months washout
- Aligns with original Khavinson protocols; ideal for telomerase research with defined endpoints
- Continuous NAD+ with Pulsed Epithalon
- 50–100 mg daily, year-round
- 5–10 mg daily for 10–20 days, cycled every 4–6 months
- NAD+ morning throughout year, Epithalon evening during active cycles only
- Epithalon: 10–20 days per cycle; NAD+: continuous
- Maintains mitochondrial support continuously while pulsing telomerase activation; most common in longevity research
- High-Dose Intermittent NAD+ with Standard Epithalon
- 200–300 mg NAD+ 2–3× weekly
- NAD+ post-workout or fasted state; Epithalon evening during active cycle
- Epithalon: 10–20 days; NAD+: ongoing intermittent
- Reduces injection frequency for NAD+; may suit metabolic or exercise performance research over pure longevity focus
- The pulsed dual stack mirrors the original Russian gerontology trials and minimizes long-term peptide exposure. Researchers pursuing telomere length studies or circadian rhythm normalization often select this model because it isolates the intervention period and allows for clear pre- and post-cycle biomarker measurement. The 4–6 month washout prevents receptor desensitization and aligns with the timeframes used in published Epithalon trials.
- Continuous NAD+ with pulsed Epithalon is the most commonly adopted model among longevity researchers. It acknowledges that NAD+ depletion is a chronic condition in aging models, not a transient state that resolves after 10–20 days of supplementation. Maintaining NAD+ year-round supports sirtuin activity, mitochondrial biogenesis, and DNA repair, while periodic Epithalon cycles target telomerase activation and pineal function during defined windows. This structure also simplifies protocol adherence—daily NAD+ injections become routine, and Epithalon cycles are scheduled events rather than ongoing obligations.
- High-dose intermittent NAD+ dosing reduces injection frequency but sacrifices stable plasma levels. NAD+ has a half-life under four hours—administering 200–300 mg twice weekly creates peaks and troughs rather than sustained support. Some researchers hypothesize that pulsed high doses may trigger greater AMPK activation or mitochondrial stress responses, but peer-reviewed evidence supporting superiority over daily dosing remains limited. This approach suits investigators prioritizing convenience or studying acute metabolic effects rather than chronic anti-aging interventions.